In this study, we address (1) the activation status of IRF5 in the course of human SLE, (2) whether IRF5 functions other than in the induction of type I IFNs, and (3) the effects of IRF5 inhibition on the SLE pathogenesis after the disease onset. The gene discussed is IRF5; the disease is systemic lupus erythematosus.